Silo Pharma (SILO) Common Equity (2010 - 2026)
Silo Pharma (SILO) posted Common Equity of $5.7 million for Q1 2026, down 9.89% sequentially from $6.3 million in Q4 2025, and up 41.65% YoY from $4.0 million in Q1 2025.
Silo Pharma (SILO) Common Equity (2010 - 2026) Analysis & Trends
Silo Pharma has reported Common Equity for 14 years, with the latest figure at $5.7 million in Q1 2026.
- Quarterly Common Equity rose 41.65% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 41.65% YoY) and the FY2025 annual result came in at $6.3 million, up 25.25% from the prior year.
- Common Equity eased to $5.7 million in Q1 2026 per SILO's latest filing, from $6.3 million in the prior quarter.
- Over five years, Common Equity peaked at $11.9 million in Q3 2022 and troughed at $4.0 million in Q1 2025.
- A 5-year average of $7.0 million and a median of $6.3 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2024: Common Equity soared 109.09% in 2022, then tumbled 43.96% in 2024.
- Over 5 years, Common Equity stood at $10.3 million in 2022, then slumped by 40.27% to $6.2 million in 2023, then retreated by 18.5% to $5.0 million in 2024, then rose by 25.25% to $6.3 million in 2025, then slipped by 9.89% to $5.7 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $5.7 million, $6.3 million, and $5.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | 9.79 Bn |
| 10 | Silo Pharma | 3.08 Mn | 3.08 Mn | - | 4.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.89 Mn |
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 6.31 Mn |
| Sep 30, 2025 | 5.01 Mn |
| Jun 30, 2025 | 4.92 Mn |
| Mar 31, 2025 | 4.01 Mn |
| Dec 31, 2024 | 5.03 Mn |
| Sep 30, 2024 | 6.78 Mn |
| Jun 30, 2024 | 5.96 Mn |
| Mar 31, 2024 | 5.29 Mn |
| Dec 31, 2023 | 6.18 Mn |
| Sep 30, 2023 | 7.50 Mn |
| Jun 30, 2023 | 8.30 Mn |
| Mar 31, 2023 | 9.44 Mn |
| Dec 31, 2022 | 10.34 Mn |
| Sep 30, 2022 | 11.85 Mn |
| Jun 30, 2022 | 7.87 Mn |
| Mar 31, 2022 | 8.50 Mn |
| Dec 31, 2021 | 9.06 Mn |
| Sep 30, 2021 | 10.15 Mn |